Pitkänen Leena, Ranta Veli-Pekka, Moilanen Hanna, Urtti Arto
Department of Pharmaceutics, University of Kuopio, P.O. Box 1627, Kuopio, 70211, Finland.
Pharm Res. 2007 Nov;24(11):2063-70. doi: 10.1007/s11095-007-9342-0. Epub 2007 Jun 2.
To characterize the binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and to predict the binding to melanin in human choroid-retinal pigment epithelium (RPE).
The shape, size and specific surface area of synthetic melanin and isolated melanin granules from bovine choroid-retinal pigment epithelium (RPE) were characterized by SEM, laser diffractometry and BET. The binding of betaxolol, metoprolol, fluorescein isothiocyanate (FITC)-labeled phosphodiesther oligonucleotides and 6-carboxyfluorescein (6-CF) to melanin was determined. The binding of beta-blockers to melanin in human choroid-RPE was estimated based on binding parameters and the melanin content in human choroid-RPE.
Bovine melanin granules were round or oval with a mean diameter of ca. 1 mum. Synthetic granules were slightly smaller and irregular and had a two times higher specific surface area than bovine melanin. Synthetic melanin bound more betaxolol and metoprolol than bovine melanin and both melanin types showed a high affinity and a low affinity binding sites. The human choroid-RPE was predicted to contain 3-19 times more melanin bound drug than unbound drug at typical therapeutic concentrations (1-1,000 ng/ml). FITC-labeled oligonucleotides and 6-CF did not bind to melanin.
The binding of lipophilic drugs to biological melanin differs from that of synthetic melanin. Lipophilic beta-blockers are expected to bind significantly to melanin in human choroid-RPE: only a small fraction of the drug being in active free form. In contrast, phosphodiesther oligonucleotides do not seem to bind to melanin.
表征倍他洛尔、美托洛尔和寡核苷酸与合成及牛眼黑色素的结合情况,并预测其与人脉络膜视网膜色素上皮(RPE)中黑色素的结合。
通过扫描电子显微镜(SEM)、激光衍射法和BET法对合成黑色素以及从牛脉络膜视网膜色素上皮(RPE)分离出的黑色素颗粒的形状、大小和比表面积进行表征。测定倍他洛尔、美托洛尔、异硫氰酸荧光素(FITC)标记的磷酸二酯寡核苷酸和6-羧基荧光素(6-CF)与黑色素的结合情况。基于结合参数和人脉络膜-RPE中的黑色素含量,估算β受体阻滞剂与人脉络膜-RPE中黑色素的结合情况。
牛黑色素颗粒呈圆形或椭圆形,平均直径约为1μm。合成颗粒稍小且不规则,比表面积是牛黑色素的两倍。合成黑色素比牛黑色素结合更多的倍他洛尔和美托洛尔,且两种黑色素类型均显示出高亲和力和低亲和力结合位点。预计在典型治疗浓度(1-1000ng/ml)下,人脉络膜-RPE中与黑色素结合的药物比未结合的药物多3-19倍。FITC标记的寡核苷酸和6-CF不与黑色素结合。
亲脂性药物与生物黑色素的结合不同于与合成黑色素的结合。预计亲脂性β受体阻滞剂与人脉络膜-RPE中的黑色素会有显著结合:只有一小部分药物以活性游离形式存在。相比之下,磷酸二酯寡核苷酸似乎不与黑色素结合。